A major burden in life science remains the cost associated with drug development. Estimated at $1B to bring a drug from preclinical research to commercialization, solutions are needed to reduce those costs. Among these solutions, Model-Informed Drug Development (MIDD) is one ofAt ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strat ...